GlaxoSmithKline receives EU approval for a new therapeutic indication for Arixtra® (fondaparinux)
Media
GSK confirmed today that the European Commission has granted an amendment of their marketing authorisation for their anti-clotting agent.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-eu-approval-for-a-new-therapeutic-indication-for-arixtra-fondaparinux/
First published: 29 September 2010
